Phase 2 data on filgotinib show a reduction in risk of flare in patients with uveitis and good tolerance in one of the first studies of a JAK inhibitor in uveitis.
Researchers studied how gender affects the reporting of patient outcomes across commonly used scoring methods and indices in the spectrum of spondyloarthritis subtypes in a multinational study.
There was a strong, but not statistically significant, signal of reduced spinal structural damage with the combination of a selective COX-2 inhibitor and a TNF inhibitor in axial spondyloarthritis.
Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.
Some identifiers of patients with isolated axial psoriatic arthritis were older age at diagnosis, psoriatic nail lesions, and absence of inflammatory back pain.